This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
PACT was a phase 3 treatment trial using a crossover design to evaluate controller therapy approaches in pediatric asthma. The registry identifies the interventions as inhaled corticosteroid and long-acting beta2-agonist therapy.
| Feature | PACT |
|---|---|
| Official title | Pediatric Asthma Controller Trial (PACT) |
| NCT identifier | NCT00272506 |
| Phase | Phase 3 |
| Status | Completed |
| Condition | Asthma; Lung Diseases |
| Primary purpose | Treatment |
| Design model | Crossover |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
2. Clinical Question
The central clinical question was how controller therapy strategies involving inhaled corticosteroid and long-acting beta2-agonist therapy compare within the context of a pediatric asthma crossover trial.
Population
Children with asthma enrolled in the Pediatric Asthma Controller Trial.
Interventions
Inhaled corticosteroid and long-acting beta2-agonist therapies were evaluated as study interventions.
Comparator
The crossover design indicates that participants experienced more than one treatment condition during the study period.
Primary question
What differences are observed between controller therapy strategies in this pediatric asthma population?
3. Trial Design
4. Endpoints
The ClinicalTrials.gov record does not report registered primary endpoints for PACT.
5. Planned Analysis
No results are posted on ClinicalTrials.gov for this trial. The registry reports the study design and interventions but does not provide statistical analyses or endpoint results.
For a crossover treatment trial, statistical analysis would typically account for the paired structure of the data because each participant contributes information under more than one treatment condition. Depending on the endpoint type, analyses may include paired comparisons, mixed-effects models, or other models that account for within-participant correlation.
The key statistical advantage of a crossover design is that each participant can serve as their own comparison, reducing variability from stable differences between individuals.
6. Statistical Methodology
Why crossover designs require special analysis
Unlike a parallel-group trial, a crossover trial measures treatment effects within the same participant. The analysis must recognize that repeated measurements from the same person are correlated rather than independent observations.
Within-participant comparisons
The crossover structure allows investigators to compare outcomes observed under different treatment periods while controlling for participant-level characteristics that remain constant throughout the study.
Potential period and carryover effects
Crossover trials require attention to whether outcomes differ because of the treatment itself, the order in which treatments were received, or residual effects from an earlier treatment period. These considerations are central to the interpretation of crossover studies.
7. Statistical Methods Explained
Why use a crossover design?
A crossover design can improve efficiency because each participant contributes data under multiple treatment conditions. This can reduce variability compared with comparing completely separate groups.
Why are participants not treated as independent observations?
Measurements from the same child are related. Ignoring this correlation can underestimate uncertainty and lead to incorrect statistical conclusions.
What is a treatment-period effect?
A treatment-period effect occurs when outcomes differ depending on when a treatment is received rather than only because of the treatment itself.
What is a carryover effect?
A carryover effect occurs when the influence of a treatment persists into a later treatment period. Adequate design and analysis strategies are needed to evaluate this possibility.
Why are baseline characteristics less central in crossover trials?
Because participants serve as their own comparisons, stable participant characteristics are controlled more directly than in a traditional parallel-group design.
8. Limitations
- No posted results: The registry does not report statistical analyses or outcomes for this trial.
- Crossover assumptions: Interpretation of crossover studies depends on assumptions regarding treatment periods and potential carryover effects.
- Endpoint uncertainty: Registered endpoint definitions and time frames are not reported in the available registry record.
- Generalizability: Applicability depends on the characteristics of the pediatric asthma population enrolled in the study.
9. Why This Trial Matters Statistically
PACT is useful as a statistical teaching example because it illustrates the analysis considerations created by crossover treatment designs.
| Concept | How it appears in PACT |
|---|---|
| Crossover design | Participants experience multiple treatment conditions. |
| Within-participant analysis | Treatment comparisons account for repeated observations from the same participant. |
| Correlation | Repeated measurements require methods that recognize dependence. |
| Carryover assessment | Residual treatment effects are an important crossover consideration. |
| Clinical trial methodology | Demonstrates how design determines statistical analysis. |
10. Related Tutorials
Learn more about the methods used in this trial:
11. Related Calculators
12. Sources
- ClinicalTrials.gov: NCT00272506.
Continue through the Clinical Biostats knowledge graph
Connect clinical trial designs with statistical methods, tutorials, and analysis tools.
13. Record Summary
PACT demonstrates the importance of aligning statistical methodology with clinical trial design. As a phase 3 crossover study of controller therapies in pediatric asthma, the trial highlights the role of within-participant comparisons, correlation-aware analysis, and careful interpretation of crossover assumptions.